Your browser is no longer supported. Please, upgrade your browser.
Settings
FATE FATE THERAPEUTICS INC daily Stock Chart
FATE [NASD]
FATE THERAPEUTICS INC
Index- P/E- EPS (ttm)-1.07 Insider Own0.20% Shs Outstand40.04M Perf Week9.29%
Market Cap183.78M Forward P/E- EPS next Y-0.87 Insider Trans- Shs Float40.04M Perf Month4.32%
Income-33.50M PEG- EPS next Q-0.20 Inst Own74.90% Short Float0.72% Perf Quarter50.00%
Sales4.40M P/S41.77 EPS this Y10.50% Inst Trans0.32% Short Ratio0.71 Perf Half Y91.24%
Book/sh1.96 P/B2.34 EPS next Y1.10% ROA-53.10% Target Price7.00 Perf Year108.64%
Cash/sh2.30 P/C2.00 EPS next 5Y- ROE-87.80% 52W Range1.47 - 5.68 Perf YTD82.87%
Dividend- P/FCF- EPS past 5Y-8.50% ROI-38.10% 52W High-19.19% Beta1.63
Dividend %- Quick Ratio6.10 Sales past 5Y30.30% Gross Margin- 52W Low212.24% ATR0.26
Employees66 Current Ratio6.10 Sales Q/Q-9.10% Oper. Margin- RSI (14)56.04 Volatility5.60% 5.57%
OptionableNo Debt/Eq0.15 EPS Q/Q17.80% Profit Margin- Rel Volume0.36 Prev Close4.64
ShortableYes LT Debt/Eq0.03 EarningsMar 16 AMC Payout- Avg Volume405.78K Price4.59
Recom1.70 SMA203.81% SMA508.59% SMA20052.22% Volume145,503 Change-1.08%
Nov-08-16Reiterated Wedbush Outperform $8 → $7
Sep-22-16Initiated ROTH Capital Buy $8
Jul-28-16Resumed H.C. Wainwright Buy $9
Dec-04-15Initiated Wells Fargo Outperform
Oct-06-15Initiated Raymond James Outperform $8
Jun-01-15Initiated Leerink Partners Outperform $10
May-11-15Reiterated H.C. Wainwright Buy $9 → $11
Sep-08-14Initiated H.C. Wainwright Buy $9
Oct-28-13Initiated Cowen Outperform
Apr-20-17 08:00AM  Fate Therapeutics to Present at the 5th Annual Cell & Gene Therapy Investor Day GlobeNewswire
Apr-07-17 04:31PM  ETFs with exposure to Fate Therapeutics, Inc. : April 7, 2017 Capital Cube
Mar-28-17 08:51AM  Surging Earnings Estimates Signal Good News for Fate Therapeutics (FATE) Zacks
Mar-27-17 03:56PM  ETFs with exposure to Fate Therapeutics, Inc. : March 27, 2017 Capital Cube
03:56PM  ETFs with exposure to Fate Therapeutics, Inc. : March 27, 2017
Mar-23-17 01:04PM  FATE THERAPEUTICS INC Financials +5.45%
Mar-21-17 11:31AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube -9.22%
11:31AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
09:55AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
Mar-17-17 08:33AM  A Data-Rich Year Has Analysts Accepting Their Fate Therapeutics Trade Benzinga +6.68%
Mar-16-17 04:02PM  FATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:01PM  Fate Therapeutics Reports Fourth Quarter 2016 Financial Results GlobeNewswire
Mar-13-17 08:00AM  Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy GlobeNewswire +5.21%
Mar-09-17 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire +11.27%
Mar-08-17 09:30AM  Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro
Mar-07-17 02:41PM  Explosive Stocks Under $10 Zacks
Mar-02-17 04:01PM  Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting GlobeNewswire
Mar-01-17 04:01PM  Fate Therapeutics to Present at Two Upcoming Conferences in March GlobeNewswire
Feb-27-17 08:00AM  Fate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Translation of Engineered iPSC-Derived Natural Killer Cell Cancer Immunotherapy GlobeNewswire
Feb-22-17 08:22AM  Fate Therapeutics (FATE) Shares March Higher, Can It Continue?
Feb-20-17 07:52AM  Forget Alexion, Buy these 4 Biotech Stocks Instead
Feb-14-17 09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics +6.71%
Feb-13-17 09:14AM  Forget Gilead, Buy These 5 Biotech Stocks Instead
Feb-08-17 04:01PM  Fate Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference GlobeNewswire
Jan-20-17 04:36AM  Fate Therapeutics (FATE) Shares March Higher, Can It Continue?
Jan-05-17 08:00AM  Fate Therapeutics Announces First Patient Treated in ProTmune PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease GlobeNewswire
Dec-12-16 11:44PM  How Zafgen Inc (ZFGN) Stacks Up Against Its Peers at Insider Monkey
Nov-29-16 06:04AM  FATE THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial
Nov-22-16 07:07PM  Fate Therapeutics Inc (FATE) Stock: Soaring On Financing And EU Approval at Insider Monkey +10.53%
02:22PM  Rotation Is the Name of the Game
08:31AM  FATE THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Sec
08:00AM  Fate Therapeutics Announces Private Financing GlobeNewswire
Nov-10-16 12:19PM  ETFs with exposure to Fate Therapeutics, Inc. : November 10, 2016
Nov-09-16 11:55AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
Nov-07-16 05:02PM  Fate Therapeutics reports 3Q loss
04:07PM  FATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:01PM  Fate Therapeutics Reports Third Quarter 2016 Financial Results GlobeNewswire
Nov-03-16 04:59PM  Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting GlobeNewswire -5.41%
Oct-31-16 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2016 Financial Results on November 7, 2016 GlobeNewswire
Oct-05-16 08:00AM  Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions GlobeNewswire
Sep-26-16 10:15AM  4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate at 24/7 Wall St.
08:00AM  Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune in Allogeneic Hematopoietic Cell Transplantation GlobeNewswire
Sep-23-16 10:36AM  Can The Uptrend Continue for Fate Therapeutics (FATE)?
Sep-22-16 08:02AM  Coverage initiated on Fate Therapeutics by ROTH Capital +11.32%
Sep-13-16 09:43AM  5 Biotech Stocks That Are Broker Favorites
Sep-09-16 10:44AM  ETFs with exposure to Fate Therapeutics, Inc. : September 9, 2016
Sep-07-16 04:03PM  FATE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies GlobeNewswire
Aug-31-16 04:01PM  Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-29-16 11:23AM  ETFs with exposure to Fate Therapeutics, Inc. : August 29, 2016
Aug-12-16 02:21PM  ETFs with exposure to Fate Therapeutics, Inc. : August 12, 2016 +7.56%
Aug-11-16 11:13AM  Fate Therapeutics, Inc. :FATE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
Aug-10-16 04:01PM  Fate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference GlobeNewswire -7.57%
Aug-09-16 08:15AM  Fate Therapeutics (FATE) Jumps: Stock Moves 22.8% Higher
Aug-08-16 07:15PM  Fate Therapeutics reports 2Q loss +22.75%
04:03PM  FATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:01PM  Fate Therapeutics Reports Second Quarter 2016 Financial Results GlobeNewswire
08:00AM  Fate Therapeutics Announces $10.3 Million Common Stock Private Placement GlobeNewswire
Aug-02-16 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2016 Financial Results on August 8, 2016 GlobeNewswire
Aug-01-16 08:56AM  Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Jul-29-16 08:15AM  Fate Therapeutics (FATE) Catches Eye: Stock Rises 5.9%
Jul-26-16 08:01AM  Fate Therapeutics Announces Issuance of U.S. Patent on Compositions of Human Induced Pluripotent Cells GlobeNewswire
Jun-21-16 11:46AM  Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up -5.50%
08:25AM  Fate Therapeutics (FATE) Catches Eye: Stock Jumps 19.1%
Jun-20-16 11:21AM  Heres Why Traders Are Buzzing About These Five Stocks on Monday at Insider Monkey +19.05%
08:40AM  Could This Be a Turning Point for Fate Therapeutics? at 24/7 Wall St.
08:01AM  Fate Therapeutics Announces FDA Fast Track Designation for ProTmune GlobeNewswire
Jun-16-16 08:01AM  Fate Therapeutics to Host Off-the-Shelf Cancer Immunotherapy Focus Session at 2016 Annual Meeting of International Society for Stem Cell Research GlobeNewswire
Jun-11-16 11:01AM  Fate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases GlobeNewswire
May-17-16 08:01AM  Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer GlobeNewswire
May-16-16 08:01AM  Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy GlobeNewswire
May-12-16 05:30PM  FATE THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events -5.92%
May-09-16 05:12PM  Fate Therapeutics reports 1Q loss
04:41PM  FATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:01PM  Fate Therapeutics Reports First Quarter 2016 Financial Results GlobeNewswire
May-02-16 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016 GlobeNewswire
Apr-11-16 08:15AM  Fate Therapeutics (FATE) Jumps: Stock Moves 6.5% Higher
Apr-05-16 04:01PM  Fate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference GlobeNewswire
Mar-04-16 07:14AM  5 Stocks Poised for Big Breakouts at TheStreet +7.65%
Mar-03-16 04:54PM  Fate Therapeutics reports 4Q loss +7.65%
04:04PM  FATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
Feb-29-16 08:15AM  Fate Therapeutics (FATE) Catches Eye: Stock Rises 8.3%
Feb-25-16 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016 GlobeNewswire +11.92%
Feb-21-16 08:01AM  Fate Therapeutics to Present Preclinical Data for ProTmune at 2016 BMT Tandem Meetings GlobeNewswire
Feb-04-16 01:40PM  Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues +8.57%
Feb-03-16 04:01PM  Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference GlobeNewswire -14.63%
Feb-01-16 08:00AM  Biotech Sector Report; Potential Rebound for These Four Biotech Securities Accesswire
Jan-27-16 02:00PM  Fate (FATE) to Move ProTmune into Phase I/II Study in Mid-16 -11.69%
10:34AM  Fate Therapeutics Gives Up Gains After Early Morning Surge
Jan-26-16 05:23PM  Total System Services, Lannett And Fate Therapeutics Moving After-Hours
04:54PM  Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection at noodls
04:36PM  Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection GlobeNewswire
Jan-14-16 04:43PM  FATE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jan-07-16 04:22PM  Edited Transcript of FATE earnings conference call or presentation 3-Nov-15 10:00pm GMT -11.76%
Jan-06-16 04:01PM  Fate Therapeutics to Present at Biotech Showcase 2016 GlobeNewswire
Dec-09-15 08:40AM  Can Fate Therapeutics (FATE) Keep the Earnings Streak Alive This Quarter?
Dec-07-15 08:01AM  FATE THERAPEUTICS INC Files SEC form 8-K, Other Events -14.25%
08:00AM  Fate Therapeutics Conference Call to Provide Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation scheduled for 8:00 am ET today
06:00AM  Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation GlobeNewswire
Dec-03-15 08:01AM  Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference GlobeNewswire
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Storgard ChrisChief Medical OfficerNov 23Buy2.6637,59399,99737,593Nov 28 03:46 PM
RASTETTER WILLIAM HDirectorNov 23Buy2.66375,939999,998459,272Nov 28 03:44 PM
Coughlin Timothy PDirectorNov 23Buy2.6656,390149,99756,390Nov 28 03:42 PM
Wolchko J ScottPresident and CEOAug 23Option Exercise1.372,5703,521142,049Aug 24 06:55 PM